IDEA4RC FHIR Implementation Guide
0.1.0 - CI Build 150

IDEA4RC FHIR Implementation Guide, published by IDEA4RC Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/idea4rc/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 IDEA4RC FHIR IG - Home Page
... 2 IDEA4RC Model Overview
... 3 IDEA4RC Detailed ERD Model
... 4 IDEA4RC Logical Models
... 5 Useful Downloads
... 6 Condition-secondaryCancer-eu-i4rc Relationships
... 7 Encounter-eu-i4rc Relationships
... 8 Condition-primaryCancer-eu-i4rc Relationships
... 9 sarcoma-cancer-stage-group Relationships
... 10 hn-cancer-stage-group Relationships
... 11 episodeOfCare-eu-i4rc Relationships
... 12 MedicationAdministration-eu-i4rc Relationships
... 13 Subject Relationships
... 14 PatientFollowUp Relationships
... 15 EpisodeEvent Relationships
... 16 HospitalPatientRecords Relationships
... 17 CancerEpisode Relationships
... 18 AdverseEvent Relationships
... 19 GeneticTestExpression Relationships
... 20 Surgery Relationships
... 21 Radiotherapy Relationships
... 22 Artifacts Summary
.... 22.1 Adverse Event
.... 22.2 Cancer Episode
.... 22.3 Clinical Stage
.... 22.4 Diagnosis
.... 22.5 Disease Extent
.... 22.6 Drugs For Treatments
.... 22.7 Episode Event
.... 22.8 Genetic Test Expression
.... 22.9 Hospital Patient Records
.... 22.10 IsolatedLimbPerfusion
.... 22.11 OverallTreatmentResponse
.... 22.12 Pathological Stage
.... 22.13 Patient
.... 22.14 Patient Follow-Up
.... 22.15 Radiotherapy
.... 22.16 RegionalDeepHyperthemia
.... 22.17 Surgery
.... 22.18 Systemic Treatment
.... 22.19 Adverse Event Model to this guide Map
.... 22.20 Cancer Episode Model to this guide Map
.... 22.21 Clinical Stage Model to this guide Map
.... 22.22 Diagnosis to this guide Map
.... 22.23 Disease Extent Model to this guide Map
.... 22.24 Drugs For Treatments Model to this guide Map
.... 22.25 Episode Event Model to this guide Map
.... 22.26 Genetic Test Expression Model to this guide Map
.... 22.27 Hospital Patient Records Model to this guide Map
.... 22.28 Isolated Limb Perfusion Model to this guide Map
.... 22.29 Overall Treatment Response Model to this guide Map
.... 22.30 Pathological Stage Model to this guide Map
.... 22.31 Patient (Subject) Model to this guide Map
.... 22.32 Patient Follow up Model to this guide Map
.... 22.33 Radiotherapy Model to this guide Map
.... 22.34 Regional Deep Hyperthemia Model to this guide Map
.... 22.35 Surgery Model to this guide Map
.... 22.36 Systemic Treatment Model to this guide Map
.... 22.37 Observation: Alcohol use
.... 22.38 Observation: Cancer Treatment
.... 22.39 Observation: Charlson Comorbidity Index
.... 22.40 Observation: Comorbidities
.... 22.41 Observation: ECOG Performance Status
.... 22.42 Observation: Karnofsky Performance Status
.... 22.43 Observation: Occurrence of the other cancer
.... 22.44 Observation: Tobacco use
.... 22.45 Patient: IDEA4RC
.... 22.46 Condition: Primary Cancer
.... 22.47 Observation: Diagnosis details
.... 22.48 Observation: Head Neck Cancer Stage Group
.... 22.49 Observation: Localized Category (Stage, Sarcoma)
.... 22.50 Observation: LocoRegional Category (Stage)
.... 22.51 Observation: Number of tumor nodules
.... 22.52 Observation: Radiological Extra-nodal extension (rENE)
.... 22.53 Observation: Sarcoma Cancer and Disease Extent Stage Group
.... 22.54 Observation: TNM Distant Metastases Category
.... 22.55 Observation: TNM Primary Tumor Category
.... 22.56 Observation: TNM Regional Nodes Category
.... 22.57 Encounter: IDEA4RC
.... 22.58 Observation: date of the last contact
.... 22.59 Observation: Status at the Last Follow Up
.... 22.60 Procedure: Surgery
.... 22.61 Procedure: Radiotherapy
.... 22.62 MedicationAdministration: Chemotherapy
.... 22.63 EpisodeOfCare: IDEA4RC
.... 22.64 AdverseEvent: IDEA4RC
.... 22.65 Bundle: IDEA4RC
.... 22.66 Condition: Metastatic Cancer
.... 22.67 Observation: Genetic Test Expression
.... 22.68 Observation: Overall Treatment
.... 22.69 Observation: test results
.... 22.70 Observation: Tumor Rupture
.... 22.71 Observation: Yes / No assertions
.... 22.72 Procedure: Immaging for Clinical Stage
.... 22.73 Procedure: Other Treatment
.... 22.74 Substance : Other Treatment
.... 22.75 Adaptive
.... 22.76 Body Location Qualifier
.... 22.77 Chemotherapy Timing
.... 22.78 Condition related to resource
.... 22.79 Histology Morphology Behavior
.... 22.80 Laterality Qualifier
.... 22.81 Medication Outcome
.... 22.82 Performed Timing
.... 22.83 Previous Status
.... 22.84 Race Extension
.... 22.85 Radiotherapy Dose Delivered To Volume Extension
.... 22.86 Radiotherapy Energy or Isotope
.... 22.87 Radiotherapy Modality And Technique Extension
.... 22.88 Radiotherapy Modality Extension
.... 22.89 Radiotherapy Number of Sessions Extension
.... 22.90 Radiotherapy Setting
.... 22.91 Radiotherapy Technique Extension
.... 22.92 Relapse Type
.... 22.93 Same custodian flag
.... 22.94 Same Hospital
.... 22.95 Total High Dose Delivered
.... 22.96 Immaging Body sites
.... 22.97 Immaging Clinical Stage
.... 22.98 Immaging Clinical Stage Metastasis
.... 22.99 Immaging Clinical Stage Neck
.... 22.100 Immaging Clinical Stage Primary Site
.... 22.101 Adverse Event Type
.... 22.102 Affected Organs (surgery)
.... 22.103 Alcohol Usage Status: Athena
.... 22.104 Alcohol Usage Status: SNOMED CT
.... 22.105 Antineoplastic and immunostimulating agents
.... 22.106 Beam Quality
.... 22.107 Body site qualifier
.... 22.108 Calculated|Estimated
.... 22.109 Cancer Diagnosis: Athena
.... 22.110 Cancer histology behaviour: Athena
.... 22.111 Cancer histology subgroup: Athena
.... 22.112 Cancer histology: Athena
.... 22.113 Cancer site: Athena
.... 22.114 Cancer Stage Grading: Athena
.... 22.115 Cancer Stage Group Value Clinical: Athena
.... 22.116 Cancer Stage Group Value Pathological: Athena
.... 22.117 Cancer Stage Group Value: Athena
.... 22.118 Cancer Stage Group: Athena
.... 22.119 Chemotherapy cumulative dose units
.... 22.120 Chemotherapy Info
.... 22.121 Clinical TNM Primary Tumor Category Value Set
.... 22.122 Coded test results: Athena.
.... 22.123 Comorbidities: Athena
.... 22.124 Comorbidities: SNOMED
.... 22.125 Country: athena
.... 22.126 Current Smoking Status: Athena
.... 22.127 Disease Status: Athena
.... 22.128 Drugs for Systemic Treatment
.... 22.129 Drugs for Treatments
.... 22.130 ECOG Performance Status
.... 22.131 Event Type
.... 22.132 Extranodal Extension
.... 22.133 Gender: Athena
.... 22.134 Genetic test expression
.... 22.135 Genetic Tests performed (Yes/no/Unk)
.... 22.136 Genito urinary subsite: Athena
.... 22.137 HNC ConditionList: Athena
.... 22.138 Hypopharynx subsite: Athena
.... 22.139 Hypopharynx subsite: Snomed CT
.... 22.140 Intra abdominal subsite: Athena
.... 22.141 Intra thoracic subsite : Athena
.... 22.142 Larynx subsite: Athena
.... 22.143 Larynx subsite: Snomed CT
.... 22.144 Lip subsite: Athena
.... 22.145 Lip subsite: Snomed CT
.... 22.146 Margins After Surgery
.... 22.147 Metastatis: Athena
.... 22.148 Mitotic Index: Athena.
.... 22.149 Nasal cavity and paranasal sinuses subsite: Athena
.... 22.150 Nasal cavity and paranasal sinuses subsite: Snomed CT
.... 22.151 Nasopharynx subsite: Athena
.... 22.152 Nasopharynx subsite: Snomed CT
.... 22.153 New Cancer Topography
.... 22.154 Not Performed|Unknown
.... 22.155 Observation Codes for Distant Metastases Category
.... 22.156 Observation Codes for Primary Tumor Category
.... 22.157 Observation Codes for Regional Node Category
.... 22.158 Occurrence of other cancer
.... 22.159 Oral cavity subsite: Athena
.... 22.160 Oral cavity subsite: Snomed CT
.... 22.161 Oropharynx subsite: Athena
.... 22.162 Oropharynx subsite: Snomed CT
.... 22.163 Other Treatment Procedure Type
.... 22.164 Pathological M
.... 22.165 Pathological N
.... 22.166 Pathological T
.... 22.167 Pathological TNM Primary Tumor Category Value Set
.... 22.168 Positive-Negative-No Test: Athena
.... 22.169 Positive-Negative-No Test: Athena
.... 22.170 Race
.... 22.171 Radiotherapy Device Type
.... 22.172 Radiotherapy Site Laterality Qualifier
.... 22.173 Radiotherapy Sites
.... 22.174 Re-irradiation reason
.... 22.175 Reason to End Treatment
.... 22.176 Regimen
.... 22.177 Sarcoma Staging: localized disease
.... 22.178 Sarcome List: Athena
.... 22.179 Setting Radiotherapy
.... 22.180 Simple measures
.... 22.181 Site of metastasis
.... 22.182 Site rare (IDEA4RC)
.... 22.183 Site: Athena
.... 22.184 Smoking Status: LOINC
.... 22.185 Staging: loco-regional category
.... 22.186 Status at the Last Follow Up
.... 22.187 Subsites: Athena
.... 22.188 Subsites: SNOMED CT
.... 22.189 Surgery Complication
.... 22.190 Surgery Intention
.... 22.191 Surgery Location Qualifier
.... 22.192 Surgery Outcome
.... 22.193 Surgery Site Laterality Qualifier
.... 22.194 Surgery Sites
.... 22.195 Surgical Complications
.... 22.196 Surgical Procedure Category
.... 22.197 Surgical Procedure Type
.... 22.198 TNM Distant Metastases Category Value Set (Clinical)
.... 22.199 TNM Distant Metastases Category Value Set (Pathological)
.... 22.200 TNM Primary Tumor Category Value Set
.... 22.201 TNM Regional Nodes Category Value Set (Clinical)
.... 22.202 TNM Regional Nodes Category Value Set (Pathological)
.... 22.203 Tobacco Product
.... 22.204 Treatment completed as planned
.... 22.205 Treatment Response
.... 22.206 Treatment Setting
.... 22.207 Treatment Technique
.... 22.208 Trunk wall subsite: Athena
.... 22.209 Type of Biopsy
.... 22.210 Type of Diagnosis
.... 22.211 Type of surgical approach
.... 22.212 Type of Systemic Treatment
.... 22.213 Type of Treatment
.... 22.214 Types of Yes/No observations
.... 22.215 Upper and Lower limbs subsite: Athena
.... 22.216 Yes-No-Unk: Athena
.... 22.217 IDEA4RC Body Topography Code System
.... 22.218 IDEA4RC Code System
.... 22.219 IDEA4RC Vocabulary Code System
.... 22.220 Genetic Test to this guide Map
.... 22.221 HN Stage Model to this guide Map
.... 22.222 Other Treatment to this guide Map
.... 22.223 Stage Model to this guide Map
.... 22.224 Actor: Head and Neck
.... 22.225 Actor: Sarcoma
.... 22.226 Condition: Grade 2 tumor with several body sites and evidences
.... 22.227 Condition: Metastasis bone and pleura
.... 22.228 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED
.... 22.229 Condition: Stable Disease
.... 22.230 encounter-id-14
.... 22.231 EpisodeOfCare
.... 22.232 GOFSH-GENERATED-id-28
.... 22.233 GOFSH-GENERATED-id-30
.... 22.234 GOFSH-GENERATED-id-36
.... 22.235 Observation: Alcohol use
.... 22.236 Observation: BMI
.... 22.237 Observation: C reactive protein Positive
.... 22.238 Observation: Charlson Comorbidity Index
.... 22.239 Observation: comorbidity
.... 22.240 Observation: date of the last contact
.... 22.241 Observation: Diagnosis
.... 22.242 Observation: Dimension of Tumor
.... 22.243 Observation: Distant metastases clinical M1
.... 22.244 Observation: Distant metastases pathology M1
.... 22.245 Observation: ECOG Performance Status score
.... 22.246 Observation: Epstein Barr virus DNA Negative
.... 22.247 Observation: gene Mutation Analysis Performed yes
.... 22.248 Observation: Human papilloma virus Negative
.... 22.249 Observation: immunohiostochemestry analysis performed
.... 22.250 Observation: Karnofsky Performance Status score
.... 22.251 Observation: Number of mitoses per HPF
.... 22.252 Observation: Occurrence of other Cancer: Hamartoma
.... 22.253 Observation: Primary tumor clinical T0
.... 22.254 Observation: Primary tumor pathological T0
.... 22.255 Observation: Radiological Extra-nodal extension
.... 22.256 Observation: Regional lymph nodes Clinical N1
.... 22.257 Observation: Regional lymph nodes pathology N3b
.... 22.258 Observation: Surgery treatment occurred
.... 22.259 Observation: TNM clinical stage grouping
.... 22.260 Observation: TNM pathology stage grouping
.... 22.261 Observation: Tobacco use panel
.... 22.262 Patient: race extension
.... 22.263 Procedure: Isolated limb perfusion